NONE PROMYELOCYTIC AML TREATED WITH IDA OR DNR OBSERVATION

To verify the superiority of idarubicin to daunorubicin in the field of respond on initial induction of none promyelocytic AML in the real world practices of Zhujiang hospital hematology department and investigate other clinical characteristics corelated with long term survive in these patients, the information of such patients who had at lest once of hospitalization in zhujiang hospital from Jan. 2019 to Sept. 2021 were collected. The complete remission rate of idarubicin included "3+7" regimen was significantly higher than that of daunorubicin included regimen after the initial induction. But the induction regimen was not independently corelated with induction remission. The cytogenetic risk classification and gender were the factors relating to remission with sitatistical significancy. The OS and PFS both significantly corelated with stem cell transplantation, meanwhile OS also significantly corelated with chemotherapy refractory feature. To those none favourable cytogenetic risk classified patients who had underwent transplantation, onset age was the only statistically independent factor corelated with OS, PFS and even time to relapse after transplantation. But we also found the initial induction regimen was another independent factor associated with relapse time after transplantation. The data told us in the real world practices, idarubicin induction was a better regimen to induct remission than daunorubicin in newly diagnosed none promyelocytic AML especially in the none favourable risk group or female group. But the long term survive of none promyelocytic AML more depended on later acceptance of transplantation or none chemotherapy refractory respondance. For those none favourable risk patients with transplantation, older onset age was still an unfavourable predictive factor to long term survive and idarubicin induction was a favourable predictive factor to postpone relapse after transplantation.